Welcome to our dedicated page for Orgenesis news (Ticker: ORGS), a resource for investors and traders seeking the latest updates and insights on Orgenesis stock.
Orgenesis Inc. (ORGS) generates frequent news as a global biotech company focused on cell and gene therapies (CGTs) and a decentralized approach to cell processing. News about the company often highlights progress on its therapeutic pipeline, developments in its decentralized platforms, and key financing and strategic agreements that shape its business trajectory.
Recent announcements include positive real-world study results for ORG-101, a CD19 CAR-T therapy for patients with CD19+ Acute Lymphoblastic Leukemia, along with plans to initiate Phase 1/2 multicenter clinical studies at hospitals in Greece supported by an Enterprise Greece grant. Orgenesis has also reported the acquisition of GMP-validated platforms for producing CAR-T, tumor-infiltrating lymphocytes, lentivirus vectors, oncolytic virus cell carriers, and therapeutic exosomes, which it integrates into its decentralized production model.
News coverage also follows Orgenesis’ corporate and strategic moves. The company has announced a joint venture with Harley Street Healthcare Group to develop wellness and longevity services and products, including immune cell banking and regenerative therapies. It has reported a strategic collaboration to manufacture, co-market, distribute, and service its Orgenesis Mobile Processing Units and Labs (OMPULs), as well as partnerships and grants that support decentralized production of Advanced Therapy Medicinal Products and therapeutic exosomes.
Investors and observers can also track financing developments, such as equity investments, an equity line of credit with Williamsburg Venture Holdings, and a Convertible Loan Agreement involving Theracell, an indirect subsidiary. Trading venue updates, including a reverse stock split and the transition from Nasdaq to the OTCQX Best Market under the ORGS symbol, are additional recurring topics. This news page aggregates these earnings updates, clinical milestones, partnership announcements, financing transactions, and regulatory disclosures in one place for ongoing monitoring.
Orgenesis (NASDAQ: ORGS) has launched its BioShield Program aimed at accelerating the discovery and validation of neutralizing antibodies to combat viral outbreaks like COVID-19. The program will utilize its POCare anti-viral technologies to enhance immune response in animal models and could facilitate rapid identification of human neutralizing antibodies for antiviral therapies. Orgenesis is collaborating with partners from the Belgian biotech sector, including UCLouvain, to develop this initiative and improve preparedness against future pandemics.
Orgenesis Inc. (NASDAQ: ORGS) has entered into a Clinical Study Agreement with The Edith Wolfson Medical Center in Israel to conduct a clinical trial focused on validating its proprietary POCare Technologies. These technologies aim to improve the generation and expansion of tumor infiltrating lymphocytes (TIL) for cancer therapies. The automated cell culturing system is designed to simplify and optimize this process, potentially lowering manufacturing costs. Both parties expect this collaboration to advance cell and gene therapy products, providing high-quality solutions for cancer patients worldwide.
Orgenesis (NASDAQ: ORGS) has formed a research collaboration with Hospital Infantil Universitario Niño Jesús in Madrid, Spain, to establish a point-of-care center using its POCare Platform. This partnership aims to optimize and manufacture cell and gene therapies utilizing Orgenesis' proprietary technologies. The initial focus will be on developing T-cell and dendritic cell-based therapies, with plans to advance oncolytic cell therapy, Celyvir, for treating solid metastatic tumors. Both parties aim to reduce costs and improve the quality of therapy delivery.
Orgenesis Inc. (NASDAQ: ORGS) announced a stock repurchase plan, allowing up to $10 million in common stock buybacks. The plan begins on May 29, 2020, and will be funded from the company's working capital, which was approximately $107 million as of March 31, 2020. This buyback reflects management's belief that the current share price does not represent the company's true value. CEO Vered Caplan highlighted the positive impact of the recent sale of Masthercell, which generated around $127 million, bolstering the company's balance sheet and growth prospects in cell and gene therapies.
Orgenesis Inc (NASDAQ: ORGS) announced the launch of its cell-based vaccine platform targeting SARS-CoV-2 and other viral diseases, including Zika and Dengue Fever. The platform utilizes irradiated permissive cells to activate immune responses, potentially offering an affordable vaccine solution. The company is set to begin animal testing for the COVID-19 vaccine and aims for future human trials, pending regulatory approvals. This initiative builds upon extensive R&D and is part of Orgenesis's broader strategy to innovate in cell and gene therapies.
Orgenesis Inc (NASDAQ: ORGS), a global biotech company, reported remarkable financial growth for Q1 2020, achieving a 348% increase in revenue to $1.9 million compared to $0.4 million in Q1 2019. The company also recorded a net income of $75.6 million per share, largely due to the sale of Masthercell. With $107.1 million in cash, Orgenesis is well-positioned for future growth, focusing on partnerships in cell and gene therapy and the development of anti-viral therapies including ranpirnase. The firm aims to deliver affordable treatments through its POCare Network.
Summary not available.
Summary not available.